The 2026 ASCO Annual Meeting featured several studies that may influence cancer care across disease settings. These 5 highlights reflect emerging advances in targeted therapy, immunotherapy, and multidisciplinary treatment approaches with potential implications for patient navigation.
The phase 3 PROTEUS trial evaluated whether adding apalutamide to androgen deprivation therapy (ADT) before and after radical prostatectomy could improve outcomes for patients with high-risk localized or locally advanced prostate cancer.1
A total of 2109 patients were randomized to receive perioperative apalutamide plus ADT or placebo plus ADT. At a median follow-up of 61.7 months, apalutamide significantly improved both primary end points. Rates of pathologic complete response or minimal residual disease were higher with apalutamide plus ADT than with placebo plus ADT (8.9% vs 1.0%; odds ratio, 10.17).
Metastasis-free survival was also improved, with a 20% reduction in the risk of distant metastasis or death (hazard ratio [HR], 0.80). Five-year metastasis-free survival rates were 78.2% and 73.5%, respectively. Improvements were also observed across secondary end points, including event-free survival (EFS) and time to subsequent therapy. Overall survival (OS) data remain immature.
Grade 3-4 treatment-emergent adverse events occurred in 39.6% of patients receiving apalutamide plus ADT and 31.0% of those receiving placebo plus ADT. Treatment discontinuation due to adverse events was relatively uncommon (7.4% vs 2.7%, respectively).
For patient navigators, the findings highlight the growing role of multidisciplinary care in earlier-stage prostate cancer and the need to support patients receiving increasingly complex treatment plans.
The phase 3 SARC041 trial evaluated the CDK4/6 inhibitor abemaciclib in patients with progressive advanced dedifferentiated liposarcoma (DDLS), a rare cancer with limited treatment options.2
A total of 108 patients were randomized to receive abemaciclib or placebo, with crossover to abemaciclib permitted after disease progression. The study demonstrated a substantial improvement in progression-free survival (PFS), with a median PFS of 9.7 months versus 1.5 months, respectively (HR, 0.39).
Although objective response rates remained modest (9.3% vs 0%), prolonged disease stabilization contributed to the observed clinical benefit. Median OS had not yet been reached in the abemaciclib arm compared with 25.5 months in the placebo arm (HR, 0.55), although the study was not powered to demonstrate a statistically significant survival benefit. Interpretation of the survival findings may also be influenced by the trial’s crossover design.
The safety profile was consistent with previous experience with abemaciclib, and no new safety signals were identified.
For patient navigators, these findings underscore the importance of helping patients understand treatment expectations, manage long-term oral therapies, and access specialized sarcoma care when appropriate.
The nearly 8-month improvement in median PFS represents a meaningful advance for a disease with few effective treatment options. While OS data remain immature, CDK4 inhibition may become an important addition to the treatment landscape for advanced DDLS.
The phase 3 LIBRETTO-432 trial provides the first randomized evidence supporting a targeted adjuvant therapy approach for patients with resected RET fusion–positive non–small cell lung cancer (NSCLC).3
Patients with stage IB-IIIA disease who had completed definitive local therapy were randomized to receive selpercatinib or placebo for up to 3 years. Among patients with stage II-IIIA disease, selpercatinib reduced the risk of recurrence or death by 83% compared with placebo (HR, 0.17). The 24-month EFS rate was 92% with selpercatinib versus 61% with placebo.
Similar benefit was observed across the overall stage IB-IIIA population, with 24-month EFS rates of 94% and 70%, respectively. OS data remain immature.
The safety profile was generally consistent with prior experience with selpercatinib. The most common grade 3 or higher adverse events included elevations in alanine aminotransferase and aspartate aminotransferase levels. No new safety signals were identified.
For patient navigators, LIBRETTO-432 reinforces the importance of comprehensive biomarker testing at diagnosis. Identifying RET fusions may now influence treatment decisions not only in advanced disease but also in earlier-stage NSCLC.
Overall, the findings support an expanded role for precision oncology in early-stage lung cancer and underscore the value of ensuring appropriate molecular testing and follow-up throughout the care continuum.
The phase 3 HARMONi-6 trial evaluated ivonescimab, a dual-targeted anti–PD-1 and anti-VEGF therapy, in combination with chemotherapy for previously untreated advanced squamous NSCLC.4
A total of 532 patients received either ivonescimab plus chemotherapy or tislelizumab plus chemotherapy. At a median follow-up of 21.4 months, ivonescimab improved OS compared with the PD-1–based regimen. Median OS was 27.9 months versus 23.7 months, respectively, representing a 34% reduction in the risk of death (HR, 0.66).
The survival advantage was consistent across PD-L1 subgroups, including patients with PD-L1 expression <1%, where median OS had not yet been reached with ivonescimab compared with 18.6 months in the control arm. These findings may be particularly relevant for patients with low PD-L1 expression, a population that has historically derived less benefit from PD-1 inhibition alone.
The safety profile was generally consistent with prior experience for dual PD-1/VEGF blockade. Rates of bleeding events were slightly higher with ivonescimab than with the comparator regimen, but no unexpected safety signals were identified.
Because the study was conducted in China, additional studies are ongoing to evaluate the generalizability of these findings in broader global populations.
For patient navigators, the findings highlight ongoing efforts to improve outcomes for patients with advanced lung cancer while emphasizing the importance of treatment education, symptom monitoring, and coordination of multidisciplinary care.
The phase 3 RASolute-302 trial evaluated daraxonrasib, an oral RAS(ON) multiselective inhibitor, in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC), a setting in which treatment options remain limited.5
A total of 500 patients were randomized to receive daraxonrasib or investigator’s choice of chemotherapy. Daraxonrasib demonstrated statistically significant improvements in OS (13.2 months vs 6.6 months; HR, 0.40) and PFS (7.2 months vs 3.6 months), with benefit observed across the broader study population.
Objective response rates were also higher with daraxonrasib than with chemotherapy (31.6% vs 11.2%). In addition to improving survival outcomes, daraxonrasib delayed deterioration in patient-reported quality of life and pain compared with chemotherapy.
The safety profile was generally favorable, with fewer grade 3 or higher treatment-related adverse events and substantially lower rates of treatment discontinuation than chemotherapy. Common toxicities included rash and stomatitis, while cytopenias such as neutropenia and anemia were more common with chemotherapy.
For patient navigators, the findings are particularly relevant because oral targeted therapies often require additional patient education, adherence support, toxicity monitoring, and coordination of supportive care services. The quality-of-life findings may also be meaningful for patients facing a disease with historically limited treatment options.
These results support daraxonrasib as a potential new treatment option for patients with previously treated metastatic PDAC and may influence future treatment standards in this setting.
Keep up to date with the latest news from us via social networks:
To sign up for our print publication or e-newsletter, please enter your contact information below.
